Disease-anti-TNF | No of patients | Total No of DRP-effectiveness | Effectiveness DRP per patient | Total No of DRP-safety | Safety DRP per patient |
---|---|---|---|---|---|
RA-infliximab | 25 | 9 | 0.4 | 9 | 0.4 |
RA-etanercept | 14 | 3 | 0.2 | 18 | 1.3 |
RA-adalimumab | 17 | 5 | 0.3 | 30 | 1.8 |
AE-infliximab | 19 | 9 | 0.5 | 9 | 0.5 |
AE-etanercept | 5 | 3 | 0.6 | 13 | 2.6 |
AE-adalimumab | 5 | 3 | 0.6 | 10 | 2 |